Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Data are now accumulating on the feasibility of various treatment options even in unfit patients and there is an increased awareness that the chronological age by itself sometimes does not reflect ...

and symptoms that indicate a more active disease pattern guide treatment initiation for CLL. The International Workshop on CLL has published guidelines. At least one of the following must be ...

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14 ...

But when CLL crowds out the healthy cells in your bone marrow and you get symptoms, you may need treatment. That’s what happened to Larry Saltzman, MD, a retired family doctor in Sacramento ...

If your CLL is in the early stages, you may not need treatment right away. If you do, your treatment will depend on your cancer stage, symptoms, total health, and preferences. Treatment options ...

Venclexta, meanwhile, is already approved in two time-limited treatment regimens ... which was given the go-ahead for CLL last year, one of four FDA-approved indications. It made sales of $1.3 ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

This is the fourth US indication for ... found on the surface of CLL cells and normal B lymphocytes. Genmab and Novartis are also developing the drug as a treatment for multiple sclerosis.

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...

[6] Until large, prospective trials will demonstrate an advantage to treat earlier patients with asymptomatic CLL and high-risk ... remains a reasonable treatment option for elderly patients ...